Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr;15(83):231-41.

Adherence to targeted oral anticancer medications

Daniel M Geynisman  1 , Karen E Wickersham
Affiliations
Review

Adherence to targeted oral anticancer medications

Daniel M Geynisman et al. Discov Med. 2013 Apr.

Abstract

The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent in cancer care. Approximately 25-30% of the oncology drug pipeline involves oral agents and there are now over 50 OAMs approved by the Food and Drug Administration. This change represents a major shift in management of patients with cancer from directly observed, intermittent intravenous therapy to self-administered, oral chronic therapy. The increased prevalence of OAMs raises the issue of adherence in oncology, including understanding the challenges of adherence to OAMs. This review focuses on studies of adherence for patients taking molecularly targeted OAMs for breast cancer, chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). We then discuss barriers to adherence and studies performed to date testing interventions for improving adherence. Finally, we discuss future areas of investigation needed to define and improve adherence to OAMs in targeted therapy for cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure

The authors report no conflicts of interest.

Figures

Figure 1.
Figure 1.
Schematic of factors and barriers involved in adherence to targeted OAMs and possible ways to improve adherence.
See this image and copyright information in PMC

References

    1. Addeo R, Vincenzi B, Riccardi F, Febbraro A, Maiorino L, Incoronato P, Mabilia R, Bianco M, Russo E, Pisano A, DP S. Multicenter observational study on adherence and acceptance of lapatinib treatment in patients with HER2+ metastatic breast cancer. J Clin Oncol 29(Suppl):abstr #e11102, 2011.
    1. Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 30(5):482–487, 2012. - PubMed
    1. Banning M Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl) 21(1):10–19, 2012. - PubMed
    1. Benjamin L, Cotte FE, Philippe C, Mercier F, Bachelot T, Vidal-Trecan G. Physicians’ preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment. Eur J Cancer 48(6):912–920, 2012. - PubMed
    1. Bosworth HB, Olsen MK, Grubber JM, Neary AM, Orr MM, Powers BJ, Adams MB, Svetkey LP, Reed SD, Li Y, Dolor RJ, Oddone EZ. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med 151(10):687–695, 2009. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources